Sign In

Andrew Trister, MD PhD

Chief Medical & Scientific Officer advancing precision health @ Verily, an Alphabet company | ex-Apple, Gates Foundation

Dr. Andrew Trister is a highly experienced clinical leader and innovator with a distinguished career spanning over two decades in health technology and healthcare.

As the Chief Medical and Science Officer at Verily, Dr. Trister leads groundbreaking research, science, and population health initiatives, playing a pivotal role in driving the company's precision health strategy.

Before joining Verily, Dr. Trister held key positions at prestigious organizations such as The Bill & Melinda Gates Foundation, where he served as the Deputy Director of Digital Health and Artificial Intelligence, spearheading initiatives to tackle global health disparities.

Dr. Trister was also a founding member of Apple's Health team, where he led clinical research and machine learning efforts in collaboration with Apple's partners.

His academic background is extensive, having pursued studies in Medicine, Bioengineering, Computer Information Science, Computer Science and Engineering, and Biological Basis of Behavior at the University of Pennsylvania. He also attended Columbia High School.

Dr. Trister's contributions extend beyond Verily, having served in various leadership and advisory roles at organizations like Galvani Bioelectronics, Enya.ai, Nusano, and Neumora, showcasing his diverse expertise in the healthcare and tech sectors.

His previous affiliations with OHSU, Fred Hutch, Sage Bionetworks, and the University of Washington underline his commitment to advancing healthcare through research, innovation, and leadership.

Driven by a passion for leveraging technology and data to enhance population health and healthcare accessibility, Dr. Trister continues to be a trailblazer in the field of precision health and innovation.

Highlights

Aug 9 · linkedin

It was great to speak at ASCO Breakthrough this week on how AI is impacting how we practice oncology.

The greatest potential I see for AI in healthcare is in improving, not replacing, what physicians can do for a patient. If as an industry we can get to a point where we’re using AI and data generated within the health system to make better decisions for the next patient, we can enable faster, more precise treatment for patients across the board.

I also enjoyed meeting many of my clinical colleagues and have been so impressed with the ways that they have leveraged technologies to address the hardest problems around drug discovery, care access, and equitable population management within oncology.

In case you missed the session, you can see more details here: [https://lnkd.in/gHH8GK3j]

Jul 11 · linkedin

The early warning system facilitated by wastewater testing proves invaluable in monitoring emerging pathogens, particularly in situations where clinical surveillance or active testing for a specific virus may be limited. We saw this recently come to life with the emergence of H5N1 and the Verily team’s development of an assay to detect H5 in wastewater samples. 

In a recent article, Megan Diamond discusses the public health opportunities of wastewater surveillance amid the H5N1 outbreak, emphasizing the effectiveness of this tool and the opportunities for the data to inform public health response. I continue to be encouraged by the continued investment we’re seeing in this space from organizations across both the public and private sector.

Andrew Trister, MD PhD
Add to my network

Location

Seattle, Washington, United States